Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03292588 · ClinicalTrials.gov registry record · Phase 2
A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 335
- Enrollment target
NCT03292588: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT03292588 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 335 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (152% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03292588, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 335 participants
- Enrollment target
Study Summary
The purpose of this study is to see if treatment with a medication called Nucala® (mepolizumab), given along with standard asthma care, makes children less likely to have asthma attacks.
Primary Outcome
Exacerbations were defined as a prescription of a course of systemic corticosteroids by a clinician, initiation of a course of systemic corticosteroids by a participant, or as a hospitalization for asthma. If a participant initiated and completed a course of systemic corticosteroids without clinician involvement, this course was counted only if the study clinician agreed the treatment was warranted, and it met the following dosage: the course for prednisone, prednisolone, or methylprednisolone w
Interventions
- DRUG Placebo
- BIOLOGICAL Mepolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2017-11-07 |
| Est. Completion | 2021-04-20 |
| Phase | Phase 2 |
What the finished NCT03292588 record still lists
NCT03292588 is an interventional study that assigns participants to a tested intervention. The registered 335 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (152% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03292588 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03292588 about?
NCT03292588 is a clinical study titled "A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children". The purpose of this study is to see if treatment with a medication called Nucala® (mepolizumab), given along with standard asthma care, makes children less likely to have asthma attacks.
What is the current status of trial NCT03292588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 335 participants. The study started on 2017-11-07. Estimated completion is 2021-04-20.
What interventions are being tested in trial NCT03292588?
The interventions under investigation include: Placebo (DRUG), Mepolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03292588?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03292588's enrollment target sits among peer trials
335 142nd of 2000 higher than 1,858 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134754 · 335 participants · NA
Carbon Dioxide (CO2) Chemosensitivity and SUDEP
- NCT05554406 · 335 participants · Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- NCT06183437 · 335 participants · Phase 4
The STOP-MED CTRCD Trial
- NCT06885177 · 335 participants · NA
TECTONIC CAD IVL IDE Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI